Next Article in Journal
Role of Type I Interferons on Filovirus Pathogenesis
Previous Article in Journal / Special Issue
Feasibility Analysis of Interleukin-13 as a Target for a Therapeutic Vaccine
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessArticle
Vaccines 2019, 7(1), 21; https://doi.org/10.3390/vaccines7010021

Comparison of Immune Responses to Different Versions of VLP Associated Stabilized RSV Pre-Fusion F Protein

1
Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01655, USA
2
Program of Immunology and Microbiology, University of Massachusetts Medical School, Worcester, MA 01655, USA
*
Author to whom correspondence should be addressed.
Present Address: Dartmouth Geisel School of Medicine, Hanover, NH 03755, USA.
Present Address: The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Received: 14 January 2019 / Revised: 7 February 2019 / Accepted: 11 February 2019 / Published: 15 February 2019
Full-Text   |   PDF [2990 KB, uploaded 15 February 2019]   |  

Abstract

Efforts to develop a vaccine for respiratory syncytial virus (RSV) have primarily focused on the RSV fusion protein. The pre-fusion conformation of this protein induces the most potent neutralizing antibodies and is the focus of recent efforts in vaccine development. Following the first identification of mutations in the RSV F protein (DS-Cav1 mutant protein) that stabilized the pre-fusion conformation, other mutant stabilized pre-fusion F proteins have been described. To determine if there are differences in alternate versions of stabilized pre-fusion F proteins, we explored the use, as vaccine candidates, of virus-like particles (VLPs) containing five different pre-fusion F proteins, including the DS-Cav1 protein. The expression of these five pre-F proteins, their assembly into VLPs, their pre-fusion conformation stability in VLPs, their reactivity with anti-F monoclonal antibodies, and their induction of immune responses after the immunization of mice, were characterized, comparing VLPs containing the DS-Cav1 pre-F protein with VLPs containing four alternative pre-fusion F proteins. The concentrations of anti-F IgG induced by each VLP that blocked the binding of prototype monoclonal antibodies using two different soluble pre-fusion F proteins as targets were measured. Our results indicate that both the conformation and immunogenicity of alternative VLP associated stabilized pre-fusion RSV F proteins are different from those of DS-Cav1 VLPs. View Full-Text
Keywords: respiratory syncytial virus; VLPs; vaccine; F protein; immune responses respiratory syncytial virus; VLPs; vaccine; F protein; immune responses
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Cullen, L.M.; Schmidt, M.R.; Torres, G.M.; Capoferri, A.A.; Morrison, T.G. Comparison of Immune Responses to Different Versions of VLP Associated Stabilized RSV Pre-Fusion F Protein. Vaccines 2019, 7, 21.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top